Moderna, Inc.(MRNA) - Stock detail

Moderna, Inc.

US
MRNA
Moderna, Inc.(Listing date: 12/07/2018)

Moderna, Inc. was incorporated under Delaware law on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (mRNA) medicine. Through more than a decade of work at the intersection of science, technology, and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset, the company strives to transform the future of human health in a responsible manner and to deliver the greatest possible impact to people through mRNA medicines.

AI Rating

Rating methodology
Latest close (chg%)53.72-1.76%
Buy price
51.50
Target price56.06
Sell price51.40
P/E TTM-7.55
P/E-5.14
Confidence70%
Risk score60/100
AI Summary
Maintain existing positions due to upcoming catalysts (Q1 earnings May 1, FDA decision August) while acknowledging technical overextension and fundamental deterioration. A definitive Buy or Sell decision should await post-earnings clarity.

Alpha Score

0-10
  • Trend（Score 4/10）

    Technical analysis shows a medium-term bullish trend with short-term overbought signals, recommending Hold for existing positions and waiting for a better entry point for new buyers.

  • Valuation（Score 3/10）

    Valuation metrics reflect a market pricing the stock on future pipeline potential rather than current earnings, given the lack of profitability. The P/E ratio is negative and meaningless, the P/B ratio of 2.51 is not cheap, and the high P/S-TTM ratio of 10.96 indicates a premium valuation based entirely on anticipated future sales growth. The current price of $53.72 is towards the upper end of the recent trading range.

  • Financial strength（Score 8/10）
    The balance sheet health of Moderna, Inc. appears strong based on liquidity and solvency metrics. The company exhibits robust short-term financial health with high current and quick ratios, and a conservative capital structure with a low debt-to-asset ratio of 29.89%. The high liquidity ratios imply significant cash reserves, though monitoring the cash burn rate is essential given the substantial net losses.
  • Profitability（Score 2/10）
    Profitability metrics reveal a company in a significant post-pandemic downturn, facing steep revenue declines and mounting losses. Revenue contracted sharply, with FY2025 revenue down -39.93% year-over-year. The net margin was deeply negative at -145.16%, and the company reported a net loss of -$2.82B for FY2025. Return on Equity and Return on Assets are deeply negative, indicating the company is currently destroying shareholder value.
  • Sentiment（Score 7/10）
    Moderna's stock is at an inflection point with positive pipeline developments for flu and RSV vaccines creating a setup for significant volatility with a positive bias, despite high short interest and market skepticism.
Latest price
$53.72-1.76%
Market cap21.3B
P/E TTM-7.55
P/E-5.14
Volume13.57M
Turnover735.85M